Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis

Faizan Khan,1,2 Alvi Rahman,3 Marc Carrier,1,12,14 Clive Kearon,1 Jeffrey I Weitz,5 Sam Schulman,5,6 Francis Couturaud,7 Sabine Eichinger,9 Paul A Kyrle,8 Cecilia Becattini,9 Giancarlo Agnelli,9 Timothy A Brighton,10 Anthonie W A Lensing,11 Martin H Prins,12 Elham Sabri,2 Brian Hutton,12 Laurent Pinede,13 Mary Cushman,14 Gualtiero Palareti,15 George A Wells,1,16 Paolo Prandoni,15 Harry R Büler,17 Marc A Rodger,1,2,4 for the MARVELOUS Collaborators

Treatment were used to calculate rates for individual studies, and data were pooled using random effects meta-analysis. Sex and site of initial VTE were investigated as potential sources of between study heterogeneity.

RESULTS
18 studies involving 7515 patients were included in the analysis. The pooled rate of recurrent VTE per 100 person years after discontinuation of anticoagulant treatment was 10.3 events (95% confidence interval 8.6 to 12.1) in the first year, 6.3 (5.1 to 7.7) in the second year, 3.8 events/year (95% confidence interval 3.2 to 4.5) in years 3-5, and 3.1 events/year (1.7 to 4.9) in years 6-10. The cumulative incidence for recurrent VTE was 16% (95% confidence interval 13% to 19%) at 2 years, 25% (21% to 29%) at 5 years, and 36% (28% to 45%) at 10 years. The pooled rate of recurrent VTE per 100 person years in the first year was 11.9 events (9.6 to 14.4) for men and 8.9 events (6.8 to 11.3) for women, with a cumulative incidence for recurrent VTE of 41% (28% to 56%) and 29% (20% to 38%), respectively, at 10 years. Compared to patients with isolated pulmonary embolism, the rate of recurrent VTE was higher in patients with proximal deep vein thrombosis (rate ratio 1.4, 95% confidence interval 1.1 to 1.7) and in patients with pulmonary embolism plus deep vein thrombosis (1.5, 1.1 to 1.9). In patients with distal deep vein thrombosis, the pooled rate of recurrent VTE per 100 person years was 1.9 events (95% confidence interval 0.5 to 4.3) in the first year after anticoagulation had stopped. The case fatality rate for recurrent VTE was 4% (95% confidence interval 2% to 6%).

CONCLUSIONS
In patients with a first episode of unprovoked VTE who completed at least three months of anticoagulant treatment, the risk of recurrent VTE was 10% in the first year after treatment, 16% at two years, 25% at five years, and 36% at 10 years, with 4% of recurrent VTE events resulting in death. These estimates should inform clinical practice guidelines, enhance confidence in counselling patients of their prognosis, and help guide decision making about long term management of unprovoked VTE.
Introduction

For patients with unprovoked venous thromboembolism (VTE), comprising deep vein thrombosis and pulmonary embolism, the optimal duration of anticoagulant treatment is uncertain. After three to six months of initial anticoagulation, extended treatment is highly effective at reducing the risk of recurrent VTE, but this clinical benefit is not maintained when anticoagulation is stopped. After discontinuation of anticoagulant treatment, patients with a first unprovoked VTE have a much higher risk of recurrence compared with patients with VTE provoked by a major transient risk factor. Consequently, anticoagulant treatment is discontinued after three to six months in patients with VTE due to a major transient provoking factor, whereas current guidelines suggest extended (ie, indefinite) anticoagulation in patients with unprovoked proximal deep vein thrombosis or pulmonary embolism who have a non-high bleeding risk. This is, however, a weak (grade 2B) recommendation, in large part as a result of uncertainty in estimates of the long term risk of major bleeding if treatment is continued, and, importantly, the long term risk of recurrent VTE if anticoagulation is discontinued. Thus deciding whether patients with a first episode of unprovoked VTE should receive indefinite anticoagulation or can stop treatment after the initial three to six months, remains an important challenge.

A previous individual patient data meta-analysis of 1732 patients with unprovoked VTE from six randomised trials, reported an overall risk of recurrent VTE of about 10% per year in the first two years after discontinuation of anticoagulation. That analysis did not assess the risk of recurrent VTE in men and women separately or in patients with isolated pulmonary embolism, and it only followed patients for 24 months. Furthermore, trials in that analysis were published before 2004, whereas since then additional prospective studies have reported on the risk for recurrent VTE after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked VTE, with several of these studies having followed patients beyond 24 months and some up to 10 years. This offers an opportunity to obtain reliable estimates of the long term risk of recurrent VTE and to assess how the risk varies over time—knowledge that is crucial for deciding the need for indefinite anticoagulation, as well as defining the burden of illness in this common patient population.

Methods

We formed the Meta-Analysis of the long term Risk of recurrent Venous thromboEmboLiSm after stop­ping anticOagulation for acute Unprovoked venous thromboemboliSm (MARVELOUS) collaboration to undertake a systematic review and meta-analysis to determine the rate of a first recurrent VTE event in the first year, in the second year, in years 3-5, and in years 6-10 after discontinuation of anticoagulant treatment for a first episode of unprovoked VTE, as well as the cumulative incidence for recurrent VTE at 2, 5, and 10 years.

The study protocol was developed using guidance from the preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) statement, registered in PROSPERO and published. This systematic review and meta-analysis is reported according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines.

Search strategy and study selection

In conjunction with a medical librarian, we conducted a comprehensive systematic search (from inception to 15 March 2019) of Embase, Medline, and the Cochrane Central Register of Controlled Trials. For these searches, we combined terms related to VTE and anticoagulant treatment with those related to study design, without language restrictions (Appendix table 1 shows the systematic search strategy used for Embase). We supplemented the electronic searches by hand searching reference lists of relevant review articles, and without consideration of grey literature. Two authors (FK, AR) independently screened titles, abstracts, and full text publications, and a third author (MAR) resolved discrepancies.

Randomised controlled trials and prospective observational cohort studies were included if they were published in a peer reviewed journal; they enrolled patients with a first episode of objectively confirmed, symptomatic VTE that was either unprovoked or associated with minor transient risk factors, as defined according to the International Society on Thrombosis and Haemostasis guidance (see box 1); patients had completed at least three months of initial anticoagulation before stopping treatment, and the decision to stop anticoagulation was not influenced by stratification of the risk of VTE recurrence (eg, negative D dimer test result, clinical decision rules); patients were followed-up for at least nine months after discontinuation of anticoagulant treatment; and symptomatic recurrent VTE (as defined in individual studies) events were reported during follow-up after discontinuation of anticoagulant treatment. When more than one article included the same population of patients (ie, duplication), we included the publication with the longest follow-up.

Data extraction and quality assessment

Using a standardised form, two authors (FK, AR) independently extracted data, with clarifications requested from the study’s authors when necessary. Data were extracted on study design; number of eligible patients; average age of patients; percentage of men; number of eligible patients with isolated distal deep vein thrombosis (ie, in deep veins of the calf), proximal deep vein thrombosis (ie, in the popliteal, femoral, or iliac veins), and pulmonary embolism (with or without deep vein thrombosis); and the definition of unprovoked VTE. For the calculation of event rates, we requested the following from the authors: aggregate data on the number of recurrent VTE events (any...
Box 1: International Society on Thrombosis and Haemostasis definition of unprovoked venous thromboembolism

VTE is defined as unprovoked if the following provoking risk factors are absent:

**Persistent**
- Active cancer, defined as:
  - cancer that has not received potentially curative treatment, or
  - treatment is ongoing, or
  - evidence that treatment has not been curative

**Major transient**
- Surgery with general anaesthesia for more than 30 minutes
- Confined to bed (only “bathroom privileges”) for at least three days with an acute illness
- Caesarean section

**Minor transient**
- Surgery with general anaesthesia for less than 30 minutes
- Admission to hospital for fewer than three days with an acute illness
- Oestrogen treatment
- Pregnancy or puerperium
- Confined to bed out of hospital for at least three days with an acute illness
- Leg injury associated with reduced mobility for at least three days

VTE, and subtypes deep vein thrombosis, pulmonary embolism, pulmonary embolism plus deep vein thrombosis, and fatal pulmonary embolism), and the total number of person years of follow-up during each of the specified intervals (to ensure appropriate censoring of deaths, patients lost to follow-up and those withdrawn from study). Patients who did not satisfy our eligibility criteria (eg, those with cancer or a second unprovoked VTE event) were not included in those aggregate data.

The same two authors independently assessed the risk of bias of studies. Since our objective was to establish pooled event rates after discontinuation of anticoagulant treatment, we evaluated all studies, including each arm of a randomised trial, as an independent observational cohort. As such, the risk of bias for each observational cohort was assessed using a modified version of the Newcastle-Ottawa scale score based on three selection criteria and three outcome criteria only (criteria assessing comparability were considered irrelevant in the context of this systematic review and meta-analysis). Given data clarifications obtained from the authors of all included studies, we judged the risk of bias assessment not only at the published study level but also based on authors’ clarifications. Following quality assessment standards of a previous meta-analysis, we considered studies in our meta-analysis that met four or more of these Newcastle-Ottawa scale criteria to be of higher quality. A third author (MAR) resolved discrepancies.

**Data synthesis and analysis**

For each study cohort we calculated the rates of recurrent VTE, expressed as number of events per 100 person years, from the number of first recurrent VTE events divided by the person years of follow-up obtained from the authors of original studies and categorised by four time intervals after discontinuation of anticoagulant treatment when a first recurrence of VTE occurred: year 1 (0-12 months), year 2 (12-24 months), years 3-5, and years 6-10. We used random effects meta-analyses to pool rates from each study cohort, with cohorts weighted according to their inverse variance.

Given that we calculated rates of recurrent VTE in our analysis based on person time at risk accounting for deaths and other patient losses to follow-up, obtained from the authors of the included studies, during each of the studied intervals, we calculated the cumulative incidence for recurrent VTE at 2, 5, and 10 years after discontinuation of anticoagulation. To do this, we first determined the proportion of patients who did not experience recurrent VTE based on event rates during each of the intervals we studied. Then we determined the proportion of patients who did experience a recurrent VTE by multiplying the proportion of patients, in each year under consideration, who did not experience a recurrent VTE. For example, if the rate of recurrent VTE (per 100 person years) was 10 events in year 1, 5 events in year 2, and 4 events/year in years 3-5, then the proportion of patients who did not experience a recurrent VTE within five years was 90.0% (year 1), 95.0% (year 2), and 96.0% (year 3, 4, and 5), resulting in a cumulative incidence for recurrent VTE of 24.4% five years after discontinuation of anticoagulant treatment.

We determined the upper and lower limits of the 95% confidence interval for cumulative incidence by performing the calculations described on the upper and lower limits of the 95% confidence interval of the event rates, respectively. For example, if the rate of recurrent VTE (per 100 person years) was 10.0 events (95% confidence interval 9.0 to 11.0) in year 1 and 5.0 events (4.0 to 6.0) in year 2, resulting in a two year cumulative incidence of 14.5%, then the 95% confidence interval of the cumulative incidence was calculated as follows: using the lower bound 95% confidence intervals of 9.0 events (year 1) and 4.0 events (year 2), the proportion of patients who did not experience a recurrent VTE within two years was 91.0% (year 1)×96.0% (year 2)=87.4%, resulting in a lower bound 95% confidence interval for the cumulative incidence of 12.6%. Using the upper bound 95% confidence interval of 11.0 events (year 1) and 6.0 events (year 2), the proportion of patients who did not experience a recurrent VTE within two years was 89.0% (year 1)×94.0% (year 2)=83.7%, resulting in an upper bound 95% confidence interval for the cumulative incidence of 16.3%.

Lastly, to measure the clinical impact of disease recurrence after discontinuation of anticoagulant treatment, we determined the case fatality rate of recurrent VTE from the total number of fatal recurrent pulmonary embolism events divided by the total number of recurrent VTE events.

Heterogeneity between studies was assessed using the I² statistic, with values of 75% or greater indicating substantial heterogeneity. All meta-analyses (with a requirement for at least three cohorts of patients)
were performed using StatsDirect Version 3 (Cheshire, UK).

We performed sensitivity and subgroup analyses to investigate several potential sources of between study heterogeneity: cohorts with event rates that were outliers, cohorts randomised to receive aspirin after completing initial anticoagulant treatment, cohorts derived from randomised trials versus prospective observational studies, sex, and site of initial VTE.

**Patient and public involvement**

Patients were not involved in the design or conduct of the study. Patient partners in the CanVECTOR network (www.canvector.ca) will be involved in dissemination or knowledge translation activities, or both.

**Results**

**Search results**

Of the 1034 records identified by the literature search, 604 remained after removal of duplicates. Of these, 512 were excluded after screening of titles and abstracts, leaving 92 articles for full text screening. A further 68 articles were excluded after full text screening because they were neither a randomised controlled trial nor prospective cohort study, did not include patients with unprovoked VTE, did not systematically stop anticoagulation, did not have patient follow-up lasting for a minimum of nine months after discontinuation of anticoagulation, did not report on recurrent VTE after anticoagulation, or included duplicate patients from other included studies. Thus, 24 studies were identified as eligible for inclusion in the meta-analysis (fig 1). We requested data clarifications for person years of follow-up and recurrent VTE events during follow-up from the authors of the 24 eligible studies. Data clarifications were obtained for 18 of the studies. The remaining six studies were excluded because the published manuscript did not provide the data required for our analysis.

**Characteristics of included studies**

Eighteen studies with a total of 7515 patients were included in the analysis (fig 1). Four of the 18 studies were prospective observational cohort studies and 14 were randomised controlled trials (table 1). Fifteen studies met the criteria for the International Society on Thrombosis and Haemostasis definition of unprovoked VTE or VTE associated with minor transient risk factors (table 1). All 18 studies with 24 independent observational cohorts followed patients for one year after discontinuation of anticoagulant treatment. Thirteen studies (18 cohorts and 5078 patients) followed patients for two years, four studies (four cohorts and 2638 patients) followed patients for five years, three studies (three cohorts and 1975 patients) followed patients for 10 years after discontinuation of anticoagulation (table 1). All studies were of high quality according to the Newcastle-Ottawa scale (table 1). Appendix table 2 presents the components of the Newcastle-Ottawa scale score for all studies.

**Recurrent VTE after anticoagulation**

Table 2 presents the pooled person years of follow-up, number of events for recurrent VTE, deep vein thrombosis, pulmonary embolism, pulmonary embolism plus deep vein thrombosis, and fatal pulmonary embolism, as well as the corresponding rates and cumulative incidence for these outcomes. Appendix tables 3, 6, and 7 provide the results from individual study cohorts.

In the first year after discontinuation of anticoagulation, the pooled rate of recurrent VTE per 100 person years was 10.3 events (95% confidence interval 8.6 to 12.1; I²=81%). The rate of recurrent VTE events per 100 person years for deep vein thrombosis was 6.2 (95% confidence interval 4.8 to 7.7; I²=79%), for pulmonary embolism was 3.3 (2.4 to 4.2; I²=68%), and for pulmonary embolism plus deep vein thrombosis was 0.3 (0.1 to 0.5; I²=44%) (table 2).

In the second year after discontinuation of treatment, the pooled rate of recurrent VTE events per 100 person years was 6.3 (95% confidence interval 5.1 to 7.7; I²=56%). The rate of recurrent VTE events per 100 person years for deep vein thrombosis was 3.7 (2.8 to 4.7; I²=55%), for pulmonary embolism was 2.0 (1.4 to 2.6; I²=36%), and for pulmonary embolism plus deep vein thrombosis was 0.2 (0.1 to 0.4; I²=0%) (table 2).

In years 3-5 after discontinuation of treatment, the pooled rate of recurrent VTE per 100 person years was 3.8 events/year (95% confidence interval 3.2 to 4.5; I²=24%). The recurrent VTE events annually per 100 person years for deep vein thrombosis was 2.5 (95% confidence interval 2.0 to 2.9; I²=0%), for pulmonary embolism was 1.0 (0.4 to 1.8; I²=83%), and for pulmonary embolism plus deep vein thrombosis was 0.1 (0.0 to 0.3; I²=71%) (table 2).

During years 6-10 after discontinuation of treatment, the pooled rate of recurrent VTE per 100 person years was 3.1 events/year (95% confidence interval 1.7 to 4.9; I²=84%). The recurrent VTE events annually per 100 person years for deep vein thrombosis was 2.2 (95% confidence interval 1.0 to 3.8; I²=86%), for pulmonary embolism was 0.7 (0.2 to 1.6; I²=79%), and 0.0 for pulmonary embolism plus deep vein thrombosis was 0.0 (0.0 to 0.1; I²=0%) (table 2).

The cumulative incidence for recurrent VTE was 16.0% (95% confidence interval 13.3% to 18.8%) at 2 years, 25.2% (21.3% to 29.3%) at 5 years, and 36.1% (27.8% to 45.0%) at 10 years after discontinuation of anticoagulant treatment. The corresponding values for recurrent deep vein thrombosis were 9.7% (95% confidence interval 7.5% to 12.0%), 16.3% (12.9% to 19.5%), and 25.1% (17.2% to 33.7%), for recurrent pulmonary embolism were 5.2% (3.7% to 6.7%), 8.0% (4.0% to 11.6%), and 11.2% (5.9% to 18.4%), and for recurrent pulmonary embolism plus deep vein thrombosis were 0.5% (0.2% to 0.9%), 0.8% (0.2% to 1.8%), and 0.8% (0.2% to 2.3%) after discontinuation of anticoagulation (table 2).
Fatal recurrent pulmonary embolism and case fatality rate of recurrent VTE

After discontinuation of anticoagulation, the pooled rate of fatal recurrent pulmonary embolism events per 100 person years was 0.4 (95% confidence interval 0.2 to 0.7; I²=57%) in the first year, 0.3 (0.2 to 0.6; I²=10%) in the second year, and 0.1 (95% confidence interval 0.0 to 0.3) in both years 3-5 (I²=53%) and years 6-10 (I²=0%) (table 2). The cumulative incidence for fatal recurrent pulmonary embolism was 0.7% (95% confidence interval 0.4% to 1.3%) at 2 years, 1.0% (0.4% to 2.2%) at 5 years, and 1.5% (0.4% to 3.6%) at 10 years (table 2).

Based on 17 studies involving 6864 patients with information available on both fatal recurrent pulmonary embolism (n=49) and recurrent VTE (n=1145), the pooled case fatality rate of recurrent VTE after discontinuation of anticoagulation was 3.8% (95% confidence interval 2.0% to 6.1%; I²=59%) (fig 2), which remained constant over time (Appendix table 5).

Recurrent VTE according to sex

Among men with a first unprovoked VTE, the pooled rate of recurrent VTE per 100 person years after discontinuation of anticoagulation was 11.9 events (95% confidence interval 9.6 to 14.4; I²=76%) in the first year, 7.3 events (5.3 to 9.5; I²=63%) in the second year, 4.4 events/year (95% confidence interval 3.2 to 5.7; I²=60%) in years 3-5, and 3.8 events/year (1.6 to 6.9; I²=89%) in years 6-10 (table 3). The cumulative incidence for recurrent VTE in men was 18.3% (95% confidence interval 14.4% to 22.5%) at 2 years, 28.6% (22.3% to 35.0%) at 5 years, and 41.2% (28.4% to 55.6%) at 10 years (table 3).

Among women with a first unprovoked VTE, the pooled rate of recurrent VTE per 100 person years after discontinuation of anticoagulation was 8.9 events (95% confidence interval 6.8 to 11.3; I²=72%) in the first year, 5.2 events (3.6 to 7.0; I²=57%) in the second year, 3.0 events/year (95% confidence interval 1.6 to 4.7; I²=74%) in years 3-5, and 2.0 events/year (1.3 to 2.9; I²=0%) in years 6-10 (table 3). The cumulative incidence for recurrent VTE in women was 13.6% (95% confidence interval 10.1% to 17.5%) at 2 years, 21.2% (14.4% to 28.6%) at 5 years, and 28.8% (19.8% to 38.4%) at 10 years (table 3).

Overall, men had 1.4 times the rate of recurrent VTE compared with women (rate ratio 1.4, 95% confidence interval 1.3 to 1.6, P<0.001) (see table 5).

Recurrent VTE according to site of initial VTE

In patients with a first unprovoked distal deep vein thrombosis, the pooled rate of recurrent VTE in the first year after discontinuation of anticoagulation was 1.9 events per 100 person years (95% confidence interval 0.5 to 4.3; I²=0%) (table 4).

Among patients with a first unprovoked proximal deep vein thrombosis, the pooled rate of recurrent VTE in the first year after discontinuation of anticoagulation was 10.6 events per 100 person years (8.1 to 13.3; I²=73%). In the second year after treatment had stopped, the rate was 6.5 events per 100 person years (5.2 to 7.8; I²=0%) (table 4). The cumulative two year incidence for recurrent VTE was 16.4% (95% confidence interval 12.9% to 20.1%) (table 4).

In patients with a first unprovoked isolated pulmonary embolism, the pooled rate of recurrent VTE in the first year after discontinuation of anticoagulation was 7.7 events per 100 person years (95% confidence interval 5.6 to 10.2; I²=49%). In the second year after treatment had stopped, the rate was 4.5 events per 100 person years (2.6 to 6.8; I²=45%) (table 4). The cumulative two year incidence for recurrent VTE was 11.9% (8.1% to 16.3%) (table 4).

Among those with pulmonary embolism plus deep vein thrombosis as the initial unprovoked VTE, the pooled rate of recurrent VTE in the first year after discontinuation of anticoagulation was 10.2 events per 100 person years (6.7 to 14.2; I²=59%). In the second year after treatment had stopped, the rate was 7.6 events per 100 person years (4.7 to 11.2; I²=23%) (table 4). The cumulative two year incidence for recurrent VTE was 17.0% (95% confidence interval 11.1% to 23.8%) (table 4).

Overall, patients with distal deep vein thrombosis had a lower rate of recurrent VTE compared to patients...
Table 1 | Characteristics of studies included in meta-analysis

<table>
<thead>
<tr>
<th>Source (year)</th>
<th>Study design</th>
<th>No of patients (n=7515)</th>
<th>Men (%)</th>
<th>Age (range or SD)</th>
<th>No and site of initial VTE</th>
<th>Definition of unprovoked VTE (minor transient risk factors included)</th>
<th>Follow-up (years)*</th>
<th>Independent adjudication of outcomes</th>
<th>Overall Newcastle-Ottawa scale score (out of 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LAFIT: Keanon et al28</td>
<td>RCT</td>
<td>83</td>
<td>53.0</td>
<td>58 (16)</td>
<td>61 proximal DVT, 22 PE with or without DVT</td>
<td>International Society on Thrombosis and Haemostasis</td>
<td>2</td>
<td>Yes</td>
<td>6</td>
</tr>
<tr>
<td>WODIT-DVT: Agnelli et al29</td>
<td>RCT</td>
<td>133</td>
<td>61.2</td>
<td>67.7 (7.3)</td>
<td>133 proximal DVT</td>
<td>International Society on Thrombosis and Haemostasis</td>
<td>1</td>
<td>Yes</td>
<td>6</td>
</tr>
<tr>
<td>DOTAVK: Pinede et al30</td>
<td>RCT</td>
<td>308</td>
<td>53.0</td>
<td>58.1 (16)</td>
<td>53 distal DVT; 145 proximal DVT; 18 PE, 92 PE plus DVT</td>
<td>International Society on Thrombosis and Haemostasis</td>
<td>Yes</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Arm 1</td>
<td>161</td>
<td>47.6</td>
<td>58.2</td>
<td>61.0 (15.5)</td>
<td>30 distal DVT; 79 proximal DVT; 8 PE, 44 PE plus DVT</td>
<td>2</td>
<td>Yes</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Arm 2</td>
<td>147</td>
<td>47.0</td>
<td>58.9</td>
<td>62.9 (16.3)</td>
<td>23 distal DVT; 66 proximal DVT; 10 PE, 48 PE plus DVT</td>
<td>2</td>
<td>Yes</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Palareti et al31</td>
<td>Cohort</td>
<td>166</td>
<td>50.0</td>
<td>67 (12-91)</td>
<td>4 distal DVT; 137 proximal DVT; 25 PE plus DVT</td>
<td>International Society on Thrombosis and Haemostasis</td>
<td>2</td>
<td>Yes</td>
<td>6</td>
</tr>
<tr>
<td>PREVENT: Ridker et al32</td>
<td>RCT</td>
<td>160</td>
<td>52.9</td>
<td>67.7 (7.3)</td>
<td>20 distal DVT with or without PE; 100 proximal DVT with or without PE; 40 unspecified VTE</td>
<td>Unprovoked VTE events were defined as those that did not occur within 90 days after surgery or trauma</td>
<td>2</td>
<td>Yes</td>
<td>6</td>
</tr>
<tr>
<td>DURAC I: Schulman et al33</td>
<td>RCT</td>
<td>272</td>
<td>61.4</td>
<td>60.6 (15.4)</td>
<td>234 DVT with or without PE; 38 PE</td>
<td>International Society on Thrombosis and Haemostasis</td>
<td>10</td>
<td>Yes</td>
<td>6</td>
</tr>
<tr>
<td>Prandoni et al34</td>
<td>Cohort</td>
<td>864</td>
<td>45.2</td>
<td>66.0 (16-96)</td>
<td>735 DVT with or without PE; 129 PE</td>
<td>International Society on Thrombosis and Haemostasis</td>
<td>10</td>
<td>Yes</td>
<td>6</td>
</tr>
<tr>
<td>AESOPUS: Prandoni et al35</td>
<td>RCT</td>
<td>151</td>
<td>57.6</td>
<td>69.0 (21-89)</td>
<td>151 proximal DVT</td>
<td>International Society on Thrombosis and Haemostasis</td>
<td>2</td>
<td>Yes</td>
<td>6</td>
</tr>
<tr>
<td>EINSTEIN-Extension: Bauersachs et al36</td>
<td>RCT</td>
<td>465</td>
<td>58.5</td>
<td>57.6 (16.2)</td>
<td>267 DVT; 144 PE; 46 PE plus DVT</td>
<td>International Society on Thrombosis and Haemostasis (oestrogen treatment; pregnancy and puerperium; leg trauma with transient impairment of mobility)</td>
<td>1</td>
<td>Yes</td>
<td>6</td>
</tr>
<tr>
<td>WARFASA: Becattini et al37</td>
<td>RCT</td>
<td>402</td>
<td>61.9</td>
<td>62.1 (15.1)</td>
<td>130 proximal DVT; 18 PE, 49 PE plus DVT</td>
<td>Unprovoked VTE events were defined as those that occurred in the absence of any known persistent or temporary risk factors for VTE</td>
<td>2</td>
<td>Yes</td>
<td>6</td>
</tr>
<tr>
<td>Arm 1</td>
<td>197</td>
<td>61.9</td>
<td>62.1</td>
<td>61.9 (15.3)</td>
<td>122 proximal DVT; 37 PE, 44 PE plus DVT</td>
<td>2</td>
<td>Yes</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Arm 2</td>
<td>205</td>
<td>65.8</td>
<td>61.9</td>
<td>62.1 (15.3)</td>
<td>122 proximal DVT; 37 PE, 44 PE plus DVT</td>
<td>2</td>
<td>Yes</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>ASPIRE: Brighton et al38</td>
<td>RCT</td>
<td>822</td>
<td>54</td>
<td>54 (15.8)</td>
<td>468 proximal DVT; 231 PE, 114 PE plus DVT</td>
<td>International Society on Thrombosis and Haemostasis</td>
<td>Yes</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Arm 1</td>
<td>411</td>
<td>54</td>
<td>54</td>
<td>54 (15.8)</td>
<td>232 proximal DVT; 119 PE, 59 PE plus DVT</td>
<td>2</td>
<td>Yes</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Arm 2</td>
<td>411</td>
<td>55</td>
<td>55</td>
<td>55 (15.8)</td>
<td>236 proximal DVT; 112 PE, 56 PE plus DVT</td>
<td>2</td>
<td>Yes</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>RE-SONATE: Schulman et al39†</td>
<td>RCT</td>
<td>651</td>
<td>42.4</td>
<td>56.1 (15.5)</td>
<td>Not available</td>
<td>Patients were initially treated for more than 10 months</td>
<td>1</td>
<td>Yes</td>
<td>6</td>
</tr>
<tr>
<td>PADIS-PE: Couturaud et al40</td>
<td>RCT</td>
<td>371</td>
<td>259 PE, 112 PE plus DVT</td>
<td>International Society on Thrombosis and Haemostasis (oestrogen treatment)</td>
<td>Yes</td>
<td>6</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
with proximal deep vein thrombosis (rate ratio 0.2, 95% confidence interval 0.04 to 0.5, P<0.001), isolated pulmonary embolism (0.2, 0.05 to 0.7, P=0.009), as well as pulmonary embolism plus deep vein thrombosis (0.2, 0.03 to 0.5, P<0.001). Patients with proximal deep vein thrombosis had 1.4 times the rate of recurrent VTE of patients with isolated pulmonary embolism (1.4, 1.1 to 1.7, P=0.004), and 0.9 times the rate of recurrent VTE of patients with pulmonary embolism plus deep vein thrombosis (0.9, 0.7 to 1.2, P=0.47). Patients with pulmonary embolism plus deep vein thrombosis had 1.5 times the rate of recurrent VTE of patients with isolated pulmonary embolism (1.5, 1.1 to 1.9, P=0.005) (table 5).

Sensitivity analyses
Estimates of the rate of recurrent VTE events were not different in the overall and subgroup analyses excluding outliers or cohorts among included trials with participants randomised to receive aspirin after completing initial anticoagulant treatment, as well as in cohorts derived from either randomised trials or prospective observational studies (Appendix tables 3, 4, 6, and 7).

Discussion
In this meta-analysis of 7515 patients with a first unprovoked venous thromboembolism (VTE) event who had completed at least three months of
anticoagulant treatment, we found that the long term risk for recurrent VTE was substantial. The risk reached 10.3% in the first year after discontinuation of treatment, with a cumulative incidence of 16% at 2 years, 25% at 5 years, and 36% at 10 years.

Our observed rate of recurrent VTE in the year after discontinuation of anticoagulation is consistent with that of 9.8 events per 100 person years (95% confidence interval 8.7 to 11.2) reported in a previous individual patient data meta-analysis,5 but our study provides precise estimates for the risk of symptomatic recurrent VTE up to 10 years. Thus our findings extend the knowledge for the prognosis of unprovoked VTE. Our results indicate that after diagnosis of a first unprovoked VTE, 36% of patients will experience a recurrent VTE within 10 years after discontinuation of anticoagulant treatment, underscoring that unprovoked VTE is a chronic disease imposing a substantial long term burden.

To measure the clinical impact of VTE recurrence in this patient population, we determined the case fatality rate of recurrent VTE after discontinuation of anticoagulant treatment. Our analysis showed that after treatment for a first unprovoked VTE, 3.8% (95% confidence interval 2.0% to 6.1%) of recurrent VTE events are fatal. This case fatality rate is similar to the reported 3.6% (1.9% to 5.7%) in a previous study of patients with VTE.40

Clinicians, patients, and policymakers currently lack clear guidance on decision making about duration of anticoagulation for unprovoked VTE. To date, no randomised trial has compared the risk after 3-6 months of initial treatment with that of continuing treatment indefinitely. Furthermore, no trial that has compared durations of anticoagulant treatment for VTE has been powered to detect differences in mortality. Consequently, we must rely on indirect evidence to project absolute long term rates of recurrent VTE and major bleeding, and combine these rates with surrogate measures of mortality (ie, case fatality rate) to balance the risks and benefits of anticoagulant treatment.

Our results provide clinicians, patients, and policymakers with rigorous benchmarks as well as a management framework in which to consider the long term risks and consequences of recurrent VTE if anticoagulation is stopped. When weighed against current best estimates for risks and consequences of major bleeding if anticoagulation is continued, our results could be used to decide whether to consider indefinite anticoagulation for unprovoked VTE. For example, in a typical patient with a first episode of unprovoked VTE with a risk for recurrent VTE of 36% at 10 years, combined with a case fatality rate for recurrent VTE of 4% as determined by our analysis, the risk of death from a first recurrent VTE after discontinuation of anticoagulant treatment would be about 1.44% by 10 years. Indeed, our pooled results showed a cumulative risk of fatal VTE of 1.5% at 10 years after discontinuation of treatment. For the same patient, the annual risk for major bleeding if treatment is continued is estimated at 1.2%,1 translating to a 10 year risk for major bleeding of 11%.40 When combined with the case fatality rate for major bleeding of 11%,40 the risk of death from major bleeding if anticoagulation is continued would

Table 3 | Risk of recurrent venous thromboembolism (VTE) after discontinuation of anticoagulation in patients with a first unprovoked VTE event according to sex

<table>
<thead>
<tr>
<th>Interval after anticoagulation</th>
<th>Recurrent VTE</th>
<th>Event rate per 100 person years*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Men</td>
<td>Women</td>
</tr>
<tr>
<td>1st year</td>
<td>327.38</td>
<td>2528.1</td>
</tr>
<tr>
<td>2 year cumulative incidence, % (95% CI)</td>
<td>1738.1</td>
<td>160</td>
</tr>
<tr>
<td>2 year cumulative incidence, % (95% CI)</td>
<td>2026.8</td>
<td>160</td>
</tr>
<tr>
<td>2 year cumulative incidence, % (95% CI)</td>
<td>2026.8</td>
<td>160</td>
</tr>
<tr>
<td>2 year cumulative incidence, % (95% CI)</td>
<td>2026.8</td>
<td>160</td>
</tr>
</tbody>
</table>

*Data are event rate (95% CI); I² (%); P value unless stated otherwise. P value is for heterogeneity.
be about 1.32% at 10 years. Hence, over a 10 year horizon, patients with a first unprovoked VTE might be expected to derive a small net long term mortality benefit from continuing anticoagulation, consistent with current guidelines that suggest considering indefinite anticoagulation in patients with unprovoked proximal deep vein thrombosis or pulmonary embolism who are not at high risk for bleeding. Nevertheless, our estimation of the net mortality benefit is limited owing to the uncertainty in estimates of the long term risk of major bleeding and case fatality rate of major bleeding during extended anticoagulation in patients with a first unprovoked VTE event, which should be the focus of future research.

Because the overall reduction in mortality with indefinite anticoagulation is small, other factors that affect the risk of recurrence (eg, sex, site of initial VTE) and the risk of bleeding, as well as patient preferences, could influence decisions about whether to continue or stop treatment. We found that the cumulative risk of recurrent VTE at 10 years after discontinuation of anticoagulation was 41% in men and 29% in women with a first unprovoked VTE event. Estimating the long term mortality risks over a 10 year horizon shows that a net long term mortality benefit from continuing anticoagulation might be expected in men (1.64% risk of fatal recurrent VTE versus 1.32% risk of fatal major bleeding) but not in women (1.16% risk of fatal recurrent VTE versus 1.32% risk of fatal major bleeding). Consequently, our findings affirm the importance of considering a patient’s sex in deciding the optimal duration of treatment, suggesting that there might be a stronger argument for indefinite anticoagulation in men with a first unprovoked VTE than in women. However, given the closely balanced risks of mortality from recurrent VTE and major bleeding, as well as the lack of precise sex specific estimates of the risks for major bleeding during extended anticoagulation in this patient population, the need for an individualised, patient centred approach in the long term management of unprovoked VTE is emphasised.

Certainly, risk stratification approaches enable individualised management of unprovoked VTE. Although there appears to be no clear subgroup of men who can be identified as having low risk of recurrent VTE the prospectively validated HERDOO2 (Hyperpigmentation, Edema, or Redness in either leg; D-dimer level ≥250 μg/L; Obesity with body mass index ≥30; or Older age, ≥65 years) clinical decision rule allows about 50% of women with a first unprovoked VTE to be classified as having a low risk of recurrent VTE (3% in the year after discontinuing treatment), with a long term risk of recurrent VTE of less than 10% at eight years after discontinuing anticoagulation. On the other hand, as suggested by current guidelines, it is unlikely that patients with a major bleeding risk that exceeds 3% a year would ever experience a net long term mortality benefit from indefinite anticoagulation. Currently, however, there are no validated prediction tools to identify subgroups of patients with VTE at high risk of major bleeding. Additional findings from our study are noteworthy.

Firstly, our results show that it is unlikely that patients with a first unprovoked distal deep vein thrombosis will benefit from indefinite anticoagulation given the low rate of recurrent VTE (1.9%, 95% confidence interval 0.5% to 4.3%) in the year after discontinuation of treatment. Secondly, a cohort study suggested that patients with a first unprovoked pulmonary embolism have a higher rate of recurrent VTE after discontinuation of anticoagulation is discontinued than patients with a first unprovoked proximal deep vein thrombosis, whereas another cohort study suggested the opposite. Our meta-analysis shows that the rate of recurrent VTE after discontinuation
of anticoagulation in patients with a first unprovoked proximal deep vein thrombosis is 1.4-fold higher than in patients with a first unprovoked isolated pulmonary embolism and is comparable to the rate of recurrent VTE in patients with pulmonary embolism plus deep vein thrombosis. Thirdly, our study establishes that the absolute risk of recurrent VTE in patients with a first unprovoked VTE varies considerably over time—it is highest in the first year after treatment, reaching 10.3% (95% confidence interval 8.6% to 12.1%), declines in the second year after treatment to 6.3% (5.1% to 7.7%), and then significantly drops to an average of 3.1% to 3.8% (95% confidence interval 1.7% to 4.9%) per year in the subsequent eight years. Given current guideline recommendations on treatment duration for unprovoked VTE, this finding might help clinicians counsel patients who have already stopped treatment and want advice about resuming anticoagulation. Our results suggest that patients who have not experienced a recurrence within two years of discontinuing anticoagulant treatment are unlikely to experience a net long term mortality benefit from restarting anticoagulation.

Strengths and limitations of this study

This study has several strengths. Firstly, despite a heterogeneous population of patients with VTE in studies included in our analysis, we were able to obtain and pool data from a large number of patients specifically with a first episode of unprovoked VTE who were prospectively followed for recurrent VTE after stopping anticoagulant treatment. Secondly, with the help of data clarifications from authors of included studies, we were able to capture accurately the time varying risk for recurrent VTE by standardising the varying durations of follow-up across patient cohorts, as well as compare the rates of recurrent VTE in six relevant subgroups of patients with unprovoked VTE.

Limitations of our study include the finding of moderate to high statistical heterogeneity in the primary analyses. However, the extent of heterogeneity as measured by the $I^2$ statistic tends to be larger for meta-analyses of proportions. We were unable to fully explore the study heterogeneity through subgroup and sensitivity analyses, which could potentially be explored better with a meta-analysis of individual patient data. Secondly, owing to the lack of individual patient data, we could not account for death from causes other than pulmonary embolism as a competing event for recurrent VTE, adjust for other potentially confounding variables such as patient’s age, and explore the potential effect of an age-sex interaction on the differences in the risk of recurrent VTE observed between men and women. Lastly, we did not assess the risk of major bleeding during extended anticoagulant treatment, as well as other long term consequences of recurrent VTE that should also be considered in weighing the long term risk and benefits of anticoagulation, including the risk for post-thrombotic syndrome, chronic thromboembolic pulmonary hypertension, and quality of life.

Conclusion

In patients with a first episode of unprovoked VTE who have completed at least three months of anticoagulant treatment, the risk of recurrent VTE after discontinuing anticoagulation reached 10% in the first year, 16% at 2 years, 25% at 5 years, and 36% at 10 years, with 4% of recurrent VTE events resulting in death. These findings provide rigorous benchmarks of the long term risks and consequences of recurrent VTE that should inform clinical practice guidelines, enhance confidence in counselling patients of their prognosis, and help guide decision making about long term management of unprovoked VTE.

AUTHOR AFFILIATIONS

$^1$School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada
$^2$Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada
$^3$Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada
$^4$Ottawa Blood Disease Centre, Department of Medicine, The Ottawa Hospital, Ottawa, ON, Canada
$^5$Department of Medicine, McMaster University, and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada
$^6$Department of Obstetrics and Gynaecology, The First I.M. Sechenov Moscow State Medical University, Moscow, Russia
$^7$Department of Internal Medicine and Chest Diseases, Brest University Hospital, Brest, France
$^8$Department of Medicine I, Medical University of Vienna, Vienna, Austria
$^9$Internal and Cardiovascular Medicine, Stroke Unit, University of Perugia, Perugia, Italy
$^{10}$Department of Haematology, Prince of Wales Hospital, Sydney, Australia
$^{11}$Bayer, Leverkusen, Germany
$^{12}$Department of Epidemiology and Technology Assessment, University of Maastricht, Maastricht, Netherlands
$^{13}$Department of Internal Medicine, Infirmiere Protestante, Caluire-Lyon, France
$^{14}$Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, USA
$^{15}$Arianna Foundation on Anticoagulation, Bologna, Italy
$^{16}$Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada
$^{17}$Department of Vascular Medicine, Academic Medical Center, Amsterdam, Netherlands

Contributors: FK and MAR conceived the study. FK, AR, BH, GW, and MAR developed the design and methodology of the study. All authors were involved in the acquisition, analysis, or interpretation of data. FK and MAR drafted the manuscript and all authors critically revised the manuscript for important intellectual content. All authors gave final approval of the version to be published. FK and MAR are guarantors. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Funding: MC, CK, SS, JW, and MAR are investigators of the CanVECTOR Network; the Network receives grant funding from the Canadian Institutes of Health Research (CIHR). FK was supported by the Canada Graduate Scholarship from the Canadian Institutes of Health Research (CIHR), the CIHR Drug Safety and Effectiveness Cross-Disciplinary Training award, the Queen Elizabeth II Graduate Scholarship in Science and Technology, and is supported by the CIHR Fredrick Banting and Charles Best Doctoral Research Award. CK is supported by the Jack Hirsh Fellowship in Thromboembolism, McMaster University. MAR is supported by a Heart and Stroke Foundation Career Investigator Award and a University of Ottawa, Faculty of Medicine Tier 1 Clinical Research Chair. The funding organisations did not have any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

doi: 10.1136/bmj.l4363 | BMJ 2019;366:l4363 | the bmj

on 7 August 2019 by guest. Protected by copyright.
Competing interests: All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/coi_disclosure.pdf and declare: MC has received grants from Leo Pharma, Bristol-Myers Squibb, Bayer, Octapharma, personal fees from Sanofi Aventis, Pfizer, Boehringer Ingelheim, Leo Pharma, Bayer, Pfizer, Servier, and been on the advisory board for Leo Pharma and Sanofi Aventis, outside the submitted work. CF has received grants from Bayer, outside the submitted work. JIW has received personal fees from Bayer, Boehringer Ingelheim, Bristol Myers Squibb Daichi-Sankyo, Ionis Pharmaceuticals, Janssen, Merck, Pfizer, and Portola, outside the submitted work; SS has received grants from Boehringer Ingelheim and Octapharma, personal fees from Boehringer Ingelheim, Bayer, Daichi Sankyo, Octapharma, Sanofi, Ailylam, and Bristol-Myers-Squibb, outside the submitted work; FC has received grants from Pfizer and, personal fees from Bayer, BMS, Aztra Zeneca, leopharma, outside the submitted work; CB has received personal fees from Bayer HealthCare, Daichi Sankyo, Bristol Myers Squibb, and Servier, outside the submitted work; GA has received personal fees from Bristol-Myers-Squibb, Bayer Healthcare, Boehringer Ingelheim, and Daichi Sankyo, outside the submitted work; AWAL reports being an employee of Bayer Healthcare; MHP has received personal fees from Pfizer and Daichi Sankyo, outside the submitted work; BH has reported grants from Pfizer and Astellas, outside the submitted work; BM has no competing interests.

Ethical approval: Not required.

Data sharing: No additional data available.

Transparency: The lead author (FK) and senior author (MAR) affirm the submitted work.

No additional data available.

BMS, Roche, and Werfen, outside the submitted work. There are no disclosures of payments to the conduct of systematic reviews and meta-analysis, outside the submitted work; BH reports past research grants from Sanofi Aventis, outside the submitted work; GA has received personal fees from Bristol-Myers-Squibb, Daiichi Sankyo, Octapharma, and personal fees from Bayer; MHP has received personal fees from Pfizer and personal fees from Bayer, BMS, Astra Zeneca, leopharma, outside the submitted work; SS has received grants from Boehringer Ingelheim and Octapharma, personal fees from Boehringer Ingelheim, Bayer, Daichi Sankyo, Octapharma, Sanofi, Ailylam, and Bristol-Myers-Squibb, outside the submitted work; FC has received grants from Pfizer and, personal fees from Bayer, BMS, Aztra Zeneca, leopharma, outside the submitted work; CB has received personal fees from Bayer HealthCare, Daichi Sankyo, Bristol Myers Squibb, and Servier, outside the submitted work; BH reports past research from Cornerstone Research Group for methodologic advice related to the conduct of systematic reviews and meta-analysis, outside the submitted work; GP has received personal fees from Allergan, Pfizer, BMS, Roche, and Werfen, outside the submitted work. There are no other relationships or activities that could appear to have influenced the submitted work.


**Supplementary information:** additional tables 1-7